Zhen Wang,Dingpeng Zhang,Hiroyuki Inuzuka et al.
Zhen Wang et al.
Prostate cancer (PrCa) is the most prevalent urogenital cancer in men, marked by uncontrolled cellular growth that leads to abnormal enlargement of the prostate gland. The metastatic spread of PrCa is the primary cause of mortality, causing...
New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives [0.03%]
乳腺癌中新一代雌激素受体靶向药物的现状与未来展望
Jian Min,Xin Liu,Rouming Peng et al.
Jian Min et al.
Endocrine therapy which blocking the signaling of estrogen receptor, has long been effective for decades as a primary treatment choice for breast cancer patients expressing ER. However, the issue of drug resistance poses a significant clini...
Yang Liu,Jing Liang,Rui Zhu et al.
Yang Liu et al.
PROTAC, as a novel therapeutic drug model, has received widespread attention from the academic and pharmaceutical industries. At the same time, PROTAC technology has led many researchers to focus on developing chemical biology tool properti...
Chao Zhang,Yuna He,Xiuyun Sun et al.
Chao Zhang et al.
Epigenetics, a field that investigates alterations in gene function that can be inherited without changes in DNA sequence, encompasses molecular pathways such as histone variants, posttranslational modifications of amino acids, and covalent...
Statistical Evaluation of Absolute Change versus Responder Analysis in Clinical Trials [0.03%]
临床试验中绝对变化与应答者分析的统计评价
Peijin Wang,Sarah Peskoe,Rebecca Byrd et al.
Peijin Wang et al.
In clinical trials, the primary analysis is often either a test of absolute/relative change in a measured outcome or a corresponding responder analysis. Though each of these tests may be reasonable, determining which test is most suitable f...
Franklin Mayca Pozo,Tony Hunter,Youwei Zhang
Franklin Mayca Pozo
The classical phosphatidylinositol 3-kinases (PI3Ks) are heterodimers of p110 and p85. PIK3CA, the gene encoding the catalytic p110α subunit, is one of the most frequently mutated oncogenes in human cancers with hot spot mutations occurrin...
MDM2-BCL-XL PROTACs enable degradation of BCL-XL and stabilization of p53 [0.03%]
用于降解BCL-XL并稳定p53的MDM2-BCL-XL(PROTACs)
Mengyang Chang,Feng Gao,Jing Chen et al.
Mengyang Chang et al.
Inhibition or degradation of anti-apoptotic protein BCL-XL is a viable strategy for cancer treatment. Despite the recent development of PROTACs for degradation of BCL-XL, the E3 ligases are confined to the commonly used VHL and CRBN. Herein...
Jiaji Yue,Zhe-Sheng Chen,Xiang-Xi Xu et al.
Jiaji Yue et al.
Osteosarcoma is a primary malignant tumor of the skeleton with the morbidity of 2.5 in 1 million. The regularly on-set is in the epiphysis of the extremities with a high possibility of early metastasis, rapid progression, and poor prognosis...
Cytotoxic compounds from marine actinomycetes: Sources, Structures and Bioactivity [0.03%]
海洋放线菌中的细胞毒性化合物：来源、结构及生物活性
Ziyan Qiu,Yinshuang Wu,Kunyan Lan et al.
Ziyan Qiu et al.
Marine actinomycetes produce a substantial number of natural products with cytotoxic activity. The strains of actinomycetes were isolated from different sources like fishes, coral, sponges, seaweeds, mangroves, sediments etc. These cytotoxi...
PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective [0.03%]
招募MDM2E3连接酶的PROTAC降解剂及其最新研究进展
Xin Han,Wenyi Wei,Yi Sun
Xin Han
Mouse double minute 2 (MDM2) is an E3 ubiquitin ligase which effectively degrades tumor suppressor p53. In the past two decades, many MDM2 inhibitors that disrupt the MDM2-p53 binding have been discovered and developed. Given that the MDM2-...